Transcriptomics

Dataset Information

0

Patient-derived micro-organospheres (MOS) enable clinical precision oncology


ABSTRACT: Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE184242 | GEO | 2022/09/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA763787 | ENA
| PRJNA762992 | ENA
2022-03-28 | GSE182641 | GEO
2023-03-31 | GSE226869 | GEO
| 2400785 | ecrin-mdr-crc
2012-12-22 | E-GEOD-43112 | biostudies-arrayexpress
2014-03-13 | GSE55828 | GEO
| PRJNA757257 | ENA
2023-11-06 | GSE224183 | GEO
| PRJEB38450 | ENA